Nuoli Xinjian intends to increase its capital of 500,000 shares to the holding subsidiary Nuoli Cheng Pharmaceutical Pharmaceutical Pharmaceuticals

  • 内容
  • 评论
  • 相关

On January 4th,Current Affairs Nuoli Xinjian (872806) recently issued an announcement that Hangzhou Nuclear Nuclear Nuclear Pharmaceutical Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") holding subsidiary (hereinafter referred to as "Company") (hereinafter referred to as abbreviationDue to business development needs, with the approval of the company's general manager, it plans to increase the registered capital of Nuoli Cheng Pharmaceutical from RMB 7 million to 10 million yuan, that is, 3 million yuan in registered capital.The company's subscribed capital contributions increased from 5.5 million yuan to 6 million yuan, that is, 500,000 yuan, and the shareholding ratio decreased from 78.57%to 60%; Wang Zhangyi, other shareholders, increased its contribution from 1.5 million yuan to 2.5 million yuan.That is, the newly added 1 million yuan; the new shareholder Hangzhou Mipeng Enterprise Management Partnership (Limited Partnership) will be newly subscribed for 1.5 million yuan.

After this capital increase, Nuoli Cheng Pharmaceutical is still a company's holding subsidiary. This time foreign investment will not lead to changes in the scope of mergers, and will not harm the interests of the company and shareholders.Influence.There is no relationship between the opponent of the transaction.

The main content of the foreign investment agreement: On the basis of the original investment, the company invested RMB 500,000 to Nuoli Cheng Pharmaceutical in accordance with the terms and conditions stipulated by the agreement.; On the basis of the original investment, Wang Zhangyi invested 1 million yuan to the nuclear force and expansion method according to the terms and conditions of the agreement to increase capital and share, and subscribe to the new registered capital of Nuclear Pharmaceutical Pharmaceutical RMB 1 million;Partnership (limited partnership) invested RMB 1.5 million to Nuoli Cheng Pharmaceuticals by capital increase and expansion method, and subscribed to 1.5 million yuan in new registered capital for nuclear Licheng Pharmaceutical.

This foreign investment is based on the consideration of the company's overall development strategy in the future, which is conducive to the expansion of the company's business, improves the comprehensive competitiveness of the company, creates greater value for shareholders, and promotes the company's long -term sustainable development.It is expected to have a positive impact on the company's future financial conditions and operating results.

According to the data of digging, Nuoli Xinjian is a pharmaceutical circulation enterprise with a medical wholesale business. It is mainly engaged in the professional promotion of pharmaceutical products and the wholesale and retail of drugs.

版权声明:如非注明,此文章为本站原创文章,转载请注明: 转载自Hot news website